Syncom Formulations (India) is pleased to submit herewith the following: 1. Standalone and Consolidated Un-Audited Financial…
Syncom Formulations (India) (SYNCOMF) said it is pleased to submit herewith the following: 1. The company is valued at about ₹1,915 crore.
What happened
In a filing with the BSE on 13 November 2026 at 04:46 PM, Syncom Formulations (India) (SYNCOMF) said that it is pleased to submit herewith the following: 1. Standalone and Consolidated Un-Audited Financial Results of the company.
Company snapshot
Syncom Formulations (India) is a small-cap company, with a market value of about ₹1,915 crore.
The stock last traded at ₹20.37, against a 52-week range of ₹10.21–₹27.49 (25.9% below the high).
Before this filing the shares had moved −12.3% over the month and +33.7% over three months. Average daily turnover over the last 20 sessions was about ₹19.58 crore.
Promoters held 50.57% at the end of Q1 FY27. Foreign institutions owned 0.35% and domestic institutions 0.00%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 117 | 15.8 | 0.21 |
| Q2 FY26 | 122 | 16.6 | 0.18 |
| Q3 FY26 | 115 | 18.9 | 0.23 |
| Q4 FY26 | 135 | 25.2 | 0.27 |
| Q1 FY27 | 126 | 24.8 | 0.26 |
What history shows
BCEIE's records show 1 previous results filing from the company since May 2026.
Market-wide, 11,743 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 43% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 13 November 2026: Board meeting — Financial Results/Other business matters.
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.